As part of  our biotechnology special focus this week, TWST did an interview with the Stephen Simes, president and CEO of BioSante Pharmaceuticals (BPAX) – a speciality pharmaceutical company focusing specifically on female sexual health.

The company received good news last week, when a study was published on the effectiveness of testosterone in treating female sexual health in postmenopausal women. The study claimed that testosterone had modest but meaningful results of patients.

BioSante is currently on Phase III trials of LibiGel- a testosterone based gel  for the treatment of HSDD (hypoactive sexual desire disorder) in menopausal and postmenopausal women. The study is a positive step for them towards gaining FDA approval.

For our full interview with CEO Stephen Simes- including a complete overview of the company and its outlook for the future, click here. 

To learn more about LipiGel and the above mentioned study click here. 

This entry was posted on Thursday, November 20th, 2008 at 6:23 pm and is filed under Healthcare Stocks. You can follow any responses to this entry through the RSS 2.0 feed.